Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Neoplasm Metastasis 1Leukemia 1Keratosis, Actinic 1Head and Neck Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 6Carboplatin 6Pemetrexed 5Cisplatin 5pembrolizumab 4Paclitaxel 4Docetaxel 4sargramostim 3Taxes 3Bevacizumab 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2Radiotherapy, Conformal 2Platinum 2Etoposide 2Erlotinib Hydrochloride 2Cetuximab 2vandetanib 1tetrathiomolybdate 1spartalizumab 1sintilimab 1romidepsin 1ribociclib 1nazartinib 1naporafenib 1motexafin gadolinium 1motesanib diphosphate 1methoxyamine 1fludarabine phosphate 1canakinumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma of Lung × Solutions × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡